We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




More Accountability Needed in Gene Therapy Deaths

By Biotechdaily staff writers
Posted on 02 Oct 2007
A U.S. More...
public interest group has recently called for a moratorium on enrolling some patients in gene therapy studies.

The Recombinant DNA Advisory Committee (RAC), the U.S. body dedicated to publicly reviewing gene transfer experiments, met in September 2007 to discuss a recent death in an experiment, but offered no answers to important ethical questions raised by the tragedy.

Associate director of the Center for Genetics and Society (CGS; Oakland, CA, USA), Marcy Darnovsky, Ph.D., called on the RAC to take quick action to address these issues. "This is the only government body whose deliberations on gene transfer are in any way open to the public,” she pointed out. "If the RAC doesn't take action, these problems will disappear from the public's radar and the biotech companies' agendas.”

Sponsored by Targeted Genetics (Seattle, WA, USA), the clinical trial in question was designed to test the safety of a gene transfer product for rheumatoid arthritis. One major issue raised by the death of 36-year-old Jolee Mohr is whether patients whose conditions are not life threatening should be enrolled in gene transfer studies. Experts at the meeting disagreed on this point.

CGS's Dr. Darnovsky called for a moratorium on enrolling such subjects. "Gene transfer is an experimental procedure with significant risks,” she said. "Until scientists have a better understanding of the deaths and the hundreds of serious adverse events that have been reported but not investigated, gene transfer studies should be limited to people with life-threatening conditions and no good alternatives.”

Dr. Darnovsky also commented on one longstanding problem of the informed consent process that accompanies clinical trials. "Many patients would be astonished to learn that their own doctors are being paid to sign them up,” she said. "Some might well see this as a betrayal of trust. This sort of payment should not be allowed. Yet in this case, it was not even disclosed.”

Other departures from accepted "best practices” were raised at the meeting but not fully addressed. Some language in the Targeted Genetics consent form suggested that prospective subjects could expect medical benefits from their participation, although the goal of this stage of trials was to simply determine safety. Additionally, Ms. Mohr was asked to sign the consent form immediately rather than taking it home for further consideration.

According to experts who testified at the meeting, attribution of Ms. Mohr's death to the gene transfer procedure cannot be ruled out based on current information. The RAC, which advises the U.S. National Institutes of Health, adopted several recommendations about its role in the ongoing investigation of the direct cause of death. However, no plans for additional consideration about enrolling subjects not suffering from life-threatening conditions, or other ethical issues, were discussed.

The Center for Genetics and Society is a nonprofit information and public affairs organization working to encourage responsible uses and effective societal governance of the new human genetic and reproductive technologies.


Related Links:
Center for Genetics and Society

Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
High-Density Lipoprotein Containing Cholesterol Assay
HDL-c direct FS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.